Poster Hall
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies
Sponsored by UCB Pharma Medical Affairs
Sponsored by Novartis Pharmaceuticals Corporation
Sponsored by AbbVie Medical Affairs